Drug Profile
Research programme: Alzheimer's disease therapeutics - Humanigen
Latest Information Update: 08 Aug 2017
Price :
$50
*
At a glance
- Originator KaloBios Pharmaceuticals
- Developer Humanigen
- Class Antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Parenteral, Injection)
- 21 Oct 2009 Preclinical trials in Alzheimer's disease in USA (Parenteral)